EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?

Marin Petrić iD, Mislav Radić iD

Current Issues in Molecular Biology · 15.05.2023 · 45 (5) · 4331-4343

DOI: 10.3390/cimb45050275 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 15.05.2023. Verfasst von Marin Petrić und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, University Hospital of Split, Center of Excellence for Systemic Sc…. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. The proposed pathophysiological hypotheses of SLE are numerous, involving both innate and adaptive abnormal immune responses. SLE is characterized by the overproduction of different autoantibodies that form immune complexes, which cause damage in different organs. Current therapeutic modalities are anti-inflammatory and immunosuppressive. In the last decade, we have witnessed the development of many biologicals targeting different cytokines and other molecules. One of them is interleukin-17 (IL-17), a central cytokine of a proinflammatory process that is mediated by a group of helper T cells called Th17. Direct inhibitors of IL-17 are used in psoriatic arthritis, spondyloarthritis, and other diseases. Evidence about the therapeutic potential of Th17-targeted therapies in SLE is scarce, and probably the most promising is related to lupus nephritis. As SLE is a complex heterogeneous disease with different cytokines involved in its pathogenesis, it is highly unlikely that inhibition of only one molecule, such as IL-17, will be effective in the treatment of all clinical manifestations. Future studies should identify SLE patients that are eligible for Th17-targeted therapy.

Schlagwörter

Stichwörter der Autor:innen

guselkumabinterleukin-17interleukin-23lupus nephritissecukinumabsystemic lupus erythematosusustekinumab

Autor:innen und Institutionen

  • Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, University Hospital of Split, Center of Excellence for Systemic Sclerosis Ministry of Health Republic of Croatia, Šoltanska 1, 21000 Spl…
  • Department of Internal Medicine, School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia.

ORCID-Profile: Marin Petrić, Mislav Radić

Zitieren

APA

Petrić, M., & Radić, M. (2023). Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?. Current Issues in Molecular Biology, 45(5), 4331-4343. https://doi.org/10.3390/cimb45050275

Vancouver

Petrić M, Radić M. Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?. Current Issues in Molecular Biology. 2023;45(5):4331-4343. doi:10.3390/cimb45050275

BibTeX
@article{Petri2023,
  author = {Petrić, Marin and Radić, Mislav},
  title = {Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?},
  journal = {Current Issues in Molecular Biology},
  year = {2023},
  volume = {45},
  number = {5},
  pages = {4331--4343},
  doi = {10.3390/cimb45050275}
}
Kostenlos starten →